Sign In
to Vote &
Create Storyboards.
 
Sharyn Alfonsi reports on the unusual path fluvoxamine, a drug commonly used to treat obsessive-compulsive disorder, has had to becoming an early treatment candidate for COVID-19.
4
0
0


Storyboard
Print
Share this Article



Comment on this Article

Please Sign In to comment

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard